165 related articles for article (PubMed ID: 28050672)
1. Impact of saturable distribution in compartmental PK models: dynamics and practical use.
Peletier LA; de Winter W
J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):1-16. PubMed ID: 28050672
[TBL] [Abstract][Full Text] [Related]
2. Steady-state volume of distribution of two-compartment models with simultaneous linear and saturated elimination.
Wu X; Nekka F; Li J
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):447-59. PubMed ID: 27405818
[TBL] [Abstract][Full Text] [Related]
3. In vitro simulation of in vivo pharmacokinetic model with intravenous administration via flow rate modulation.
Chen YC; Liang W; Hu JL; He GL; Wu XJ; Liu XF; Zhang J; Hu XQ
J Pharmacokinet Pharmacodyn; 2015 Feb; 42(1):33-43. PubMed ID: 25354895
[TBL] [Abstract][Full Text] [Related]
4. [Compartment simulation models and physiologic use in pharmaco- and toxicokinetics].
Kostrzewski P
Med Pr; 1998; 49(1):83-92. PubMed ID: 9587914
[TBL] [Abstract][Full Text] [Related]
5. Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modeling.
Jaber MM; Brundage RC
J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):123-132. PubMed ID: 36617366
[TBL] [Abstract][Full Text] [Related]
6. Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models.
Pilari S; Huisinga W
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):365-405. PubMed ID: 20661651
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the possibility of the second peak of drug plasma concentration time curve after iv bolus administration from the standpoint of the traditional multi-compartmental linear pharmacokinetics.
Berezhkovskiy LM
J Pharm Sci; 2008 Jun; 97(6):2385-93. PubMed ID: 17828740
[TBL] [Abstract][Full Text] [Related]
8. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
[TBL] [Abstract][Full Text] [Related]
9. Maxsim2 - Real-time interactive simulations for computer-assisted teaching of pharmacokinetics and pharmacodynamics.
Gabrielsson J; Andersson K; Tobin G; Ingvast-Larsson C; Jirstrand M
Comput Methods Programs Biomed; 2014 Mar; 113(3):815-29. PubMed ID: 24461798
[TBL] [Abstract][Full Text] [Related]
10. Application of new measures of nonlinearity to parameter estimation and simulations in individual pharmacokinetic analyses.
Khinkis L; Crotzer M
J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):43-52. PubMed ID: 30607795
[TBL] [Abstract][Full Text] [Related]
11. Mean residence times and distribution volumes for drugs undergoing linear reversible metabolism and tissue distribution and linear or nonlinear elimination from the central compartments.
Cheng HY; Jusko WJ
Pharm Res; 1991 Apr; 8(4):508-11. PubMed ID: 1871048
[TBL] [Abstract][Full Text] [Related]
12. Impact of protein binding on receptor occupancy: a two-compartment model.
Peletier LA; Benson N; van der Graaf PH
J Theor Biol; 2010 Aug; 265(4):657-71. PubMed ID: 20561976
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
14. Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans.
Eger RR; Covell DG; Carrasquillo JA; Abrams PG; Foon KA; Reynolds JC; Schroff RW; Morgan AC; Larson SM; Weinstein JN
Cancer Res; 1987 Jun; 47(12):3328-36. PubMed ID: 3581071
[TBL] [Abstract][Full Text] [Related]
15. Use of unbound volumes of drug distribution in pharmacokinetic calculations.
Stepensky D
Eur J Pharm Sci; 2011 Jan; 42(1-2):91-8. PubMed ID: 21050885
[TBL] [Abstract][Full Text] [Related]
16. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.
Tubic M; Wagner D; Spahn-Langguth H; Bolger MB; Langguth P
Pharm Res; 2006 Aug; 23(8):1712-20. PubMed ID: 16832615
[TBL] [Abstract][Full Text] [Related]
17. On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects.
Berezhkovskiy LM
J Pharm Sci; 2011 Jun; 100(6):2482-97. PubMed ID: 21254063
[TBL] [Abstract][Full Text] [Related]
18. Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.
Dumont C; Chenel M; Mentré F
J Biopharm Stat; 2014; 24(3):471-92. PubMed ID: 24697342
[TBL] [Abstract][Full Text] [Related]
19. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics of methotrexate and therapeutic drug monitoring in children with osteosarcoma. Computer simulation using a pharmacokinetic model].
Piekarczyk A; Zimak J; Taljański W
Med Wieku Rozwoj; 2000; 4(2 Suppl 2):27-33. PubMed ID: 11178326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
